Search - tctmd.com

Displaying 1 - 20 of 66

Sort: Relevancy | Date

Presentation TCT 2016

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Presenter: Aaron V. Kaplan, Rachel Neubrander, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Editorial Comment: Current Guidelines, Device, and Anticoagulation Strategies

Presenter: Bagrat Alekyan, Grzegorz L. Kaluza, Thomas D. Stuckey

November 01, 2016

Presentation TCT 2016

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

Presenter: David P. Faxon, C. Michael Gibson, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2016

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Presenter: David P. Faxon, C. Michael Gibson, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

European Guidelines on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Presenter: David P. Faxon, C. Michael Gibson, Davide Capodanno

November 01, 2016

Presentation TCT 2016

Antiplatelet Therapy in Patients Who Need Anticoagulation: Current Guidelines, Ongoing Studies

Presenter: George D. Dangas, Debabrata Mukherjee, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

Flash Debate: Counterpoint 4D-CT Leaflet Imaging Findings Will Help to Direct Anticoagulation Therapy!

Presenter: Raj Makkar, Lars Sondergaard

October 31, 2016

Presentation TCT 2016

Trial #2 - The Essentials of ... the MATRIX Trial Access Site and Anticoagulation Type (And Infusion Duration) in ACS

Presenter: Sunil V. Rao, Harvey D. White, Salvatore Brugaletta

October 31, 2016

Presentation TCT 2016

TCT 79: Course of Early Subclinical Leaflet Thrombosis After Transcatheter Aortic Valve Replacement With or Without Oral Anticoagulation

Presenter: John M. Lasala, Philippe Pibarot, Jürgen Rothe

October 31, 2016

Presentation TCT 2016

TCT 54: LEADERS FREE OAC: Biolimus A9 Coated vs Bare Metal Stents in Patients Requiring Oral Anticoagulation. A Prespecified Subgroup Analysis of the LEADERS FREE Trial

Presenter: Neal S. Kleiman, David F. Kong, Didier Carrié

October 31, 2016

Presentation TCT 2016

Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Stefan C. Bertog

October 30, 2016

News Conference News TCT 2016

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

Yael L. Maxwell

October 30, 2016

Presentation TCT 2016

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Presenter: Paul A. Gurbel, James A. Reiffel

October 30, 2016

$Bivalirudin Versus Unfractionated Heparin Analysis: What Is Really Best in Which Patients?$

Presentation TCT 2015

Bivalirudin Versus Unfractionated Heparin Analysis: What Is Really Best in Which Patients?

Presenter: Carlo Briguori, Roxana Mehran, Carey D. Kimmelstiel

October 15, 2015

Presentation TCT 2015

MATRIX Trial Recap: Interaction Between Access Site and Antithrombin Choice in ACS

Presenter: Carlo Briguori, Roxana Mehran

October 15, 2015

Presentation TCT 2015

The REG1 Anticoagulation System: Lessons From Factor IX Inhibitor Using RNA Aptamer Technology

Presenter: Carlo Briguori, Roxana Mehran

October 15, 2015

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

Presentation TCT 2015

Alternatives to Anticoagulation: Left Atrial Appendage Occlusion Devices

Presenter: Gerhard C. Schuler, Matthew J. Price

October 14, 2015

Presentation TCT 2015

Data Gaps and Future Trial Pathways: Possible Study Designs for New Devices, Anticoagulation Ineligible Patients, and Comparative NOAC Data

Presenter: Nicole Ibrahim, Saibal Kar, Zoltan G. Turi

October 14, 2015

News Conference News TCT 2015

Manual Thrombectomy Does Not Improve Outcomes in High-Risk STEMI Patients

October 14, 2015

Advertisement

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Editorial Comment: Current Guidelines, Device, and Anticoagulation Strategies

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

European Guidelines on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Antiplatelet Therapy in Patients Who Need Anticoagulation: Current Guidelines, Ongoing Studies

Flash Debate: Counterpoint 4D-CT Leaflet Imaging Findings Will Help to Direct Anticoagulation Therapy!

Trial #2 - The Essentials of ... the MATRIX Trial Access Site and Anticoagulation Type (And Infusion Duration) in ACS

TCT 79: Course of Early Subclinical Leaflet Thrombosis After Transcatheter Aortic Valve Replacement With or Without Oral Anticoagulation

TCT 54: LEADERS FREE OAC: Biolimus A9 Coated vs Bare Metal Stents in Patients Requiring Oral Anticoagulation. A Prespecified Subgroup Analysis of the LEADERS FREE Trial

Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Bivalirudin Versus Unfractionated Heparin Analysis: What Is Really Best in Which Patients?

MATRIX Trial Recap: Interaction Between Access Site and Antithrombin Choice in ACS

The REG1 Anticoagulation System: Lessons From Factor IX Inhibitor Using RNA Aptamer Technology

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Alternatives to Anticoagulation: Left Atrial Appendage Occlusion Devices

Data Gaps and Future Trial Pathways: Possible Study Designs for New Devices, Anticoagulation Ineligible Patients, and Comparative NOAC Data

Manual Thrombectomy Does Not Improve Outcomes in High-Risk STEMI Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content